

References

L-166

1. Burgunder JM, Schöls L, Baets J, et al.; EFNS. EFNS guidelines for the molecular diagnosis of neurogenetic disorders: motoneuron, peripheral nerve and muscle disorders. *Eur J Neurol*. 2011 Feb;18(2):207-17.
2. Prior TW, Nagan N, Sugarman EA, Batish SD, Braastad C. Technical standards and guidelines for spinal muscular atrophy testing. *Genet Med*. 2011 Jul;13(7):686-94.
3. Prior TW, Russman, BS. (Updated November 2013). Spinal Muscular Atrophy. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2014.
4. Prior T; for the Professional Practice and Guidelines Committee of American College of Medical Genetics ACMG. Carrier screening for spinal muscular atrophy. *Genet Med*. 2008; 10(11):840-2.
5. American College of Obstetrics and Gynecology (ACOG) Committee on Genetics. Committee opinion No. 432: spinal muscular atrophy. *Obstet Gynecol*. 2009;113:1194-6.
6. Wang C, Finkel R, Bertini E, et al. Consensus statement for standard of care in spinal muscular atrophy. *J Child Neurol*. 2007;22;1027-49.
7. Muralidharan K, et al. Population carrier screening for spinal muscular atrophy: A position statement of the Association of Molecular Pathology." *J Mol Diag*. 2011; 13; 3-6.
8. ACOG Committee Opinion. Number 691, March 2017. Carrier Screening for Genetic Conditions *Obstet Gynecol*. 2017 Mar;129 (3):pe41-e55.
9. Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. *Genet Med*. 2013;15(6):482-3.
10. FDA News Release: FDA approves first drug for spinal muscular atrophy. Dec 2016.